non-small cell lung cancer (nScLc) is one of the most common lung cancers worldwide. Accurate prognostic stratification of NSCLC can become an important clinical reference when designing therapeutic strategies for cancer patients. With this clinical application in mind, we developed a deep neural network (Dnn) combining heterogeneous data sources of gene expression and clinical data to accurately predict the overall survival of nScLc patients. Based on microarray data from a cohort set (614 patients), seven well-known NSCLC biomarkers were used to group patients into biomarker-and biomarker+ subgroups. then, by using a systems biology approach, prognosis relevance values (pRV) were then calculated to select eight additional novel prognostic gene biomarkers. finally, the combined 15 biomarkers along with clinical data were then used to develop an integrative DNN via bimodal learning to predict the 5-year survival status of NSCLC patients with tremendously high accuracy (AUC: 0.8163, accuracy: 75.44%). Using the capability of deep learning, we believe that our prediction can be a promising index that helps oncologists and physicians develop personalized therapy and build the foundation of precision medicine in the future.Lung cancer is the worldwide leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer patients 1 . The most common NSCLC subtypes are adenocarcinoma (ADC), squamous cell carcinoma (SQC), and large cell carcinoma. Although the overall 5-year survival rate of patients diagnosed with stage I ADC was 63%, nearly 35% of patients relapsed after surgery with a poor prognosis 2 . Adjuvant treatments have been considered ideal for ADC patients with the highest risk of recurrence or death to increase survival rates 3 . Therefore, prognostic stratification is crucial for categorizing patients to help doctors make decisions on therapeutic strategies.Recently, researchers have developed predictive methods based on gene expression profiles to classify lung cancer patients with distinct clinical outcomes, including relapse and overall survival 4 . Previous studies have shown the importance of biomarkers for NSCLC, such as EPCAM, HIF1A, PKM, PTK7, ALCAM, CADM1, and SLC2A1, which were used as a single biomarker for predicting prognostic condition or metastasis 5-11 . However, cancer is a systemic disease with complicated and illusive mechanisms that often involves multiple genes and cross-talk between pathways. Therefore, extending our understanding of NSCLC via the single gene biomarkers by studying the interactions between genes is essential for more accurate prognostic prediction.Machine learning algorithms are powerful tools that apply input features (biomarkers) to capture the complicated interdependencies between these features to accurately predict clinical outcomes 12 . In addition, predicting cancer prognosis can be improved by appropriately modeling the interactions between biomarkers compared with the single biomarker approach ...